Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 13/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16038552 | 1.00 | HCAR2 (0.60) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL16038550 | 0.92 | ATM (0.50) | HCAR2ATMTSHRTP53MAPT | |
| SCHEMBL18264574 | 0.85 | ATM (0.44) | HCAR2ATMMAPTRAB9ANPSR1 | |
| SCHEMBL15499937 | 0.85 | HCAR2 (0.50) | HCAR2ATMTSHRTP53MAPT | |
| SCHEMBL28061129 | 0.83 | HCAR2 (0.63) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL2723104 | 0.82 | HCAR2 (0.57) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL8743721 | 0.82 | HCAR2 (0.57) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL2723100 | 0.82 | HCAR2 (0.57) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL11652727 | 0.81 | HCAR2 (0.55) | HCAR2ATMTSHRTP53EGLN1 | |
| SCHEMBL11658484 | 0.81 | HCAR2 (0.55) | HCAR2ATMTSHRTP53EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905298-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2024-02-20 | — | — | US | disclosed |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| EP-4230264-A2 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2023-08-23 | — | — | EP | disclosed |
| EP-3366668-B1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2023-06-21 | — | — | EP | disclosed |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2023-06-20 | — | — | US | disclosed |
| US-11230548-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-01-25 | — | — | US | disclosed |
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2021-08-10 | — | — | US | disclosed |
| US-20210122758-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2021-04-29 | — | — | US | disclosed |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-11-12 | — | — | US | disclosed |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-03-24 | — | — | US | disclosed |
| US-20180064673-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-15 | — | — | US | disclosed |
| US-20180030063-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-02-01 | — | — | US | disclosed |
| US-9775823-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-10-03 | — | — | US | disclosed |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-04-06 | — | — | US | disclosed |
| US-20160137660-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | ALKERMES PHARMA IRELAND LTD (IE) | 2016-05-19 | — | — | US | disclosed |
| EP-2970101-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | Alkermes Pharma Ireland Limited (IE) | 2016-01-20 | — | — | EP | disclosed |
| US-9090558-B2 | Prodrugs of fumarates and their use in treating various diseases | ALKERMES PHARMA IRELAND LIMITED (IE) | 2015-07-28 | — | — | US | disclosed |
| WO-2014152494-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DESEASES | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275205-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083703-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-11679092-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-10596140-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-20200352893-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-20240024275-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-20210122758-A1 | Prodrugs of Fumarates and Their Use in Treating Various Diseases | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4620/4885TSHR 1775/4885 |
| US-20140275205-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4620/4885TSHR 1775/4885 |
| US-11230548-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4620/4885TSHR 1775/4885 |
| US-20180042881-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-11905298-B2 | Prodrugs of fumarates and their use in treating various diseases | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4614/4885TSHR 1851/4885 |
| US-20180064673-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-20180030063-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4620/4885TSHR 1775/4885 |
| US-20170095439-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, FAH, GLS2 | HCAR2 613/4885ATM 3975/4885TSHR 4379/4885 |
| US-20160137660-A1 | PRODRUGS OF FUMARATES AND THEIR USE IN TREATING VARIOUS DISEASES | FH, CBR1, CBR3 | HCAR2 107/4885ATM 4620/4885TSHR 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.